Compounds > erlotinib hydrochloride

Page last updated: 2024-09-05

erlotinib hydrochloride and Alopecia Cicatrisata

erlotinib hydrochloride has been researched along with Alopecia Cicatrisata in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	5 (62.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Acquitter, M; Chiappa, AM; Dervout, C; Fleuret, C; Plantin, P	1
Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P	1
Demierre, MF; Goldberg, LJ; Pongpudpunth, M	1
Carney, D; Forde, P; Murphy, C; O'Sullivan, C	1
Drillenburg, P; Hoekzema, R	1
Anadkat, MJ; Hepper, DM; Wu, P	1
Nakamura-Wakatsuki, T; Yamamoto, T	1
Costa, DB; Kobayashi, S; Schumer, ST	1

Other Studies

8 other study(ies) available for erlotinib hydrochloride and Alopecia Cicatrisata

Article	Year
[Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation]. Annales de dermatologie et de venereologie, 2020, Volume: 147, Issue:12 Topics: Alopecia; Cicatrix; Erlotinib Hydrochloride; Erythema; Female; Folliculitis; Humans; Middle Aged; Neoplasm Recurrence, Local	2020
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PloS one, 2013, Volume: 8, Issue:7 Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53	2013
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. Journal of cutaneous pathology, 2009, Volume: 36, Issue:12 Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Lung Neoplasms; Middle Aged; Quinazolines	2009
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer. Irish journal of medical science, 2011, Volume: 180, Issue:1 Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines	2011
Folliculitis decalvans associated with erlotinib. Clinical and experimental dermatology, 2010, Volume: 35, Issue:8 Topics: Alopecia; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Folliculitis; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcus aureus	2010
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:5 Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines	2011
Purpuric drug eruption and alopecia induced by erlotinib. Dermatology online journal, 2012, May-15, Volume: 18, Issue:5 Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2012
Erlotinib-associated alopecia in a lung cancer patient. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:12 Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment	2007